JO
RLMD icon

John Overdeck’s Relmada Therapeutics RLMD Stock Holding History

John Overdeck’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Sell
214,915
-193,180
-47% -$1.35M ﹤0.01% 3279
2026
Q1 		$2.84M Sell
408,095
-164,740
-29% -$779K ﹤0.01% 2478
2025
Q4 		$2.77M Buy
572,835
+399,221
+230% +$1.34M ﹤0.01% 2189
2025
Q3 		$349K Buy
173,614
+78,197
+82% +$75K ﹤0.01% 3148
2025
Q2 		$57.3K Sell
95,417
-75,127
-44% -$38.6K ﹤0.01% 3056
2025
Q1 		$46K Buy
170,544
+42,965
+34% +$14.2K ﹤0.01% 3052
2024
Q4 		$66.3K Sell
127,579
-63,736
-33% -$155K ﹤0.01% 3017
2024
Q3 		$620K Sell
191,315
-11,946
-6% -$38.7K ﹤0.01% 2362
2024
Q2 		$610K Sell
203,261
-23,778
-10% -$86K ﹤0.01% 2271
2024
Q1 		$1.06M Sell
227,039
-75,705
-25% -$365K ﹤0.01% 1928
2023
Q4 		$1.25M Buy
302,744
+105,547
+54% +$313K ﹤0.01% 1942
2023
Q3 		$592K Sell
197,197
-107,689
-35% -$320K ﹤0.01% 2208
2023
Q2 		$750K Sell
304,886
-99,389
-25% -$275K ﹤0.01% 2115
2023
Q1 		$914K Sell
404,275
-122,887
-23% -$424K ﹤0.01% 1922
2022
Q4 		$1.84M Buy
527,162
+475,274
+916% +$4.17M 0.01% 1358
2022
Q3 		$1.92M Buy
51,888
+40,537
+357% +$1.12M 0.01% 1167
2022
Q2 		$216K Buy
11,351
+851
+8% +$18.6K ﹤0.01% 2134
2022
Q1 		$283K Buy
+10,500
New +$217K ﹤0.01% 2232

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's RLMD Position: Q2 2026 in Review

John Overdeck reduced its Relmada Therapeutics (RLMD) stake by 47% in Q2 2026, selling an estimated $1.35M and leaving 214,915 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3279.

John Overdeck first reported a position in RLMD in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.84M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • John Overdeck held 214,915 shares of Relmada Therapeutics worth $1.49M as of Q2 2026.
  • John Overdeck sold 193,180 Relmada Therapeutics shares in Q2 2026, an estimated $1.35M.
  • Relmada Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3279 holding.
  • John Overdeck first reported a position in Relmada Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • John Overdeck's Relmada Therapeutics position peaked at $2.84M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.